Effect of patient and treatment factors on persistence with antihypertensive treatment: A population-based study

PLoS One. 2021 Jan 15;16(1):e0245610. doi: 10.1371/journal.pone.0245610. eCollection 2021.

Abstract

Purpose: To analyze patterns of antihypertensive drug use among new users in a Southern European population, and identify patient- and treatment-related factors that influence persistence.

Methods: This is a retrospective observational study of new antihypertensive drug users aged ≥40 years in Aragón, Spain. Information on antihypertensive drugs (2014-2016) prescribed and dispensed at pharmacies via the public health system were collected from a regional electronic population-based pharmacy database. Persistence was assessed using the gap method. Kaplan-Meier and Cox regression analyses were conducted to analyze patterns of use and factors that influence persistence.

Results: The 25,582 new antihypertensive drug users in Aragón during the study period were prescribed antihypertensive drugs in monotherapy (73.3%), fixed combination (13.9%), free combination (9.1%), or other (3.7%). One in five received antihypertensive drugs within 15 days of the prescription date, but not after. During the first year of follow-up, 38.6% of the study population remained persistent. The likelihood of treatment discontinuation was higher for participants who were male, aged ≥80 years, and received an antihypertensive drug in monotherapy compared with fixed combination.

Conclusion: Overall persistence with antihypertensive therapy was poor, and was influenced by the sex, age and type of therapy. Fixed combinations appear to be a good choice for initial therapy, especially in patients with a higher risk of discontinuation. Nonetheless, adverse drug effects and the patient's preferences and clinical profile should be taken into account.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / adverse effects
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / mortality*
  • Male
  • Medication Adherence*
  • Middle Aged
  • Risk Factors
  • Spain / epidemiology

Substances

  • Antihypertensive Agents

Grants and funding

This work was supported by the Grupo de Investigación en Servicios Sanitarios de Aragón (GRISSA) [B09-17R] of the IIS Aragón, and funded by the regional Government of Aragón, Spain and the European Fund for Regional Development (FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.